VANDA PHARMACEUTICALS INC. Deferred Federal Income Tax Expense (Benefit)
VANDA PHARMACEUTICALS INC. (VNDA) reported Deferred Federal Income Tax Expense (Benefit) of $78.68 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-12
- VANDA PHARMACEUTICALS INC. deferred federal income tax expense (benefit) for fiscal 2025 was $78.68M.
- VANDA PHARMACEUTICALS INC. deferred federal income tax expense (benefit) for fiscal 2024 was -$4.76M.
- VANDA PHARMACEUTICALS INC. deferred federal income tax expense (benefit) for fiscal 2023 was -$2.24M, a 280.94% decline from fiscal 2022.
- VANDA PHARMACEUTICALS INC. deferred federal income tax expense (benefit) for fiscal 2022 was $1.24M, a 81.25% decline from fiscal 2021.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $78.68M 10-K · filed 2026-02-12 |
| 2024-12-31 | -$4.76M 10-K · filed 2026-02-12 |
| 2023-12-31 | -$2.24M 10-K · filed 2026-02-12 |
| 2022-12-31 | $1.24M 10-K · filed 2025-02-14 |
| 2021-12-31 | $6.60M 10-K · filed 2024-02-08 |
| 2020-12-31 | $6.08M 10-K · filed 2023-02-09 |
| 2019-12-31 | -$85.62M 10-K · filed 2022-02-24 |
| 2018-12-31 | $0.00 10-K · filed 2021-02-11 |
| 2017-12-31 | $0.00 10-K · filed 2020-02-26 |
| 2016-12-31 | $0.00 10-K · filed 2019-02-19 |
| 2015-12-31 | $0.00 10-K · filed 2018-02-15 |
| 2014-12-31 | $0.00 10-K · filed 2017-02-17 |
| 2011-12-31 | $1.82M 10-K · filed 2014-02-25 |
| 2010-12-31 | -$1.82M 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |